Shares in Clarity Pharmaceuticals Ltd (ASX: CU6) were trading more than 10% higher in early trade on Monday after the company said it was going to present data from studies of its prostate cancer detection compound at an esteemed European medical conference.

But what was perhaps more compelling in the company’s announcement was a first person account from a patient who had used the company’s compound and had benefited greatly from it.

New detection methods being developed

Clarity has developed two radiopharmaceutical compounds called 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA which its studies to date show perform well compared with existing detection methods.

The company said it will present various data relating to the compounds at the European Association of Nuclear Medicine (EANM) Annual Congress 2026, which is being held in October in Vienna.

The biotechnology company said regarding the conference:

EANM 2026 Annual Congress is one of the world’s leading nuclear medicine conferences and the acceptance of these abstracts is testament to the strength of the data generated by Clarity’s products and the promising prospects for SAR-bisPSMA to change the paradigm in the diagnosis and treatment of prostate cancer.

The company said one of its trials which will be presented, “demonstrated improved diagnostic performance of 64Cu-SAR-bisPSMA next-day imaging vs. 68Ga-PSMA-11 across all key parameters assessed, including mean number of lesions per participant, total number of lesions, true positive rate and proportion of participants with a positive scan”.

The company will also present data from three client case studies, and said the use of its compound, “changed planned clinical management in all three patients”.

One of the patients, Steve Hunter, also supplied a testimonial.

Compelling first person account

Mr Hunter said he was diagnosed with prostate cancer in 2016, and while his initial treatment was quite successful, blood tests revealed in 2023 that his cancer had returned.

He said:

With SOC PSMA imaging currently available, no lesions were detectable. I was informed by more than one doctor that what I had was a micro-metastatic version of prostate cancer; that is, I had a large number of cancers too small to be detected.

Mr Hunter, himself a medical professional with a history including oncology research, approached Clarity with a view to trying its technology.

He said:

The results were beyond my expectations. Three tumours were found and I underwent targeted external beam radiation. Since then, I have repeated this process with Clarity and (Dr Alan Taylor’s) support a few times to scan, find and subsequently treat the ensuant small number of tumours that arise, with stereotactic radiation therapy. I am so grateful to Clarity in making these scans available. This approach has proven to be highly successful by allowing me to obtain clear information about my disease and defer requiring ADT therapy and all the associated side effects with this treatment.

Clarity shares were trading 14.1% higher at $2.07.  

The post Why is this ASX biotech charging more than 10% higher? appeared first on The Motley Fool Australia.

More reading

• This beaten-down ASX gold stock is jumping on a $300 million deal
• Forget term deposits! I’d buy these two ASX 300 shares instead
• Buy, hold, sell: Wildcat Resources, NAB, Wisetech shares
• Which ASX ETF will pay an eye-popping $18 per share dividend this season?
• What are ASX 200 futures?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Monday has finally brought some relief for Ramelius Resources Ltd (ASX: RMS) shareholders.

After a rough start to 2026, the ASX gold stock is climbing after announcing a $300 million deal to sell its Edna May Gold Hub in Western Australia.

At the time of writing, the Ramelius share price is up 3.81% to $3.00 apiece. By comparison, the S&P/ASX 200 Index(ASX: XJO) is up 0.1% to 8,775 points.

That still leaves the stock down around 28% since the start of the year, although it remains 20% higher over the past 12 months.

Let’s take a closer look at the deal.

Ramelius sells Edna May

According to the release, Ramelius has entered into a binding agreement to sell the Edna May Gold Hub to Forrestania Resources Ltd (ASX: FRS).

Forrestania shares last traded at 42.5 cents before the company was placed in a trading halt.

The deal is worth $300 million upfront, made up of $200 million in cash and $100 million in Forrestania shares.

Ramelius has already received a $20 million deposit, with the rest of the cash and shares payable once the transaction is completed.

Edna May has been part of Ramelius since 2017, when it was acquired from Evolution Mining Ltd (ASX: EVN). Since then, the operation has produced around 760,000 ounces of gold.

However, the mine is not currently producing. It has been on care and maintenance duties from April 2025.

Ramelius managing director Mark Zeptner described the sale as “a logical transaction” for both companies.

Why buyers are returning today

The positive share price reaction suggests investors are happy to see Ramelius unlock value from Edna May.

The company is receiving a sizeable cash payment from an asset that is no longer producing. It also keeps some exposure to Edna May through its Forrestania shareholding.

That could be very useful if Forrestania can get the processing plant running again and build a larger regional gold business around the asset.

Ramelius said it is now focused on the transformation of its Mt Magnet operations and the development of Rebecca-Roe.

What happens next

Although the sale appears to be moving forward, keep in mind that the deal isn’t done just yet.

Forrestania still needs to secure at least $200 million in binding commitments under its proposed equity raising.

And on top of that, its shareholders also need to approve the issue of shares under the agreement.

If those conditions are met, Ramelius expects the transaction to complete in the September quarter of 2026.

The post This beaten-down ASX gold stock is jumping on a $300 million deal appeared first on The Motley Fool Australia.

More reading

• This ASX gold company’s aggressive M&A program continues with $300 million deal
• 5 ASX 200 gold stocks to buy and hold amid the crashing gold price
• 5 things to watch on the ASX 200 on Friday
• Here are the top 10 ASX 200 shares today
• 6 ASX shares upgraded by analysts this week

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Term deposits look much more appealing these days following the RBA interest rate rises. Getting a return of more than 5% with no risk sounds pretty good! But, I’d still prefer to invest in S&P/ASX 300 Index (ASX: XKO) shares for passive income.

In fact, this looks like a fantastic time to invest in names that have been impacted by elevated interest rates, but could benefit when rates are reduced again. 

I’m particularly thinking about real estate investment trusts (REITs), because they offer exposure to fairly high-yielding commercial properties, but higher rates increase debt costs and are a headwind for property values.

There are two names I really want to highlight: Centuria Industrial REIT (ASX: CIP) and Dexus Industria REIT (ASX: DXI). Both of these businesses are focused on owning industrial properties. There are three compelling reasons to look at them today.

Good dividend yield

The yields on offer from these two businesses are more appealing to me than those from term deposits.

Centuria Industrial REIT’s FY26 payout is 16.8 cents per unit, which translates into a current distribution yield of 5.45%.

Dexus Industria REIT’s FY26 payout is 16.6 cents per unit, which equates to a distribution yield of 6.8%.

Perhaps even more importantly than those impressive yields, the payouts from these two businesses can grow in the long-term thanks to rental income growth.

Rental income tailwinds

There are many different property sectors we could invest in, such as shopping centres, office buildings, storage units, childcare centres, and so on.

I think it makes the most sense to invest in businesses with sustainable income growth because that’s a key driver of profit growth, which funds passive income and supports a higher share price.

Industrial properties have a number of tailwinds, including e-commerce growth, the onshoring of supply chains, data centre growth, refrigerated space growth (for food and medicine), and Australia’s growing population.

All of the above is leading to a very low vacancy rate and solid organic revenue growth for the two ASX 300 shares.

In the third quarter of FY26, Centuria Industrial REIT reported FY26 re-leasing spreads averaged 36%, reflecting the “significant under-renting” within the portfolio and the “ongoing comparatively strong market conditions that are prevalent across Australian industrial markets, particularly within infill locations.”

In other words, the new rental contracts generated 36% more rental income than the older rental contracts.

Dexus Industria REIT’s FY26 half-year result included like-for-like income growth of 7.4%, supported by rental escalations, strong re-leasing spreads and higher average occupancy throughout the period.

That strong level of rental growth can help offset the short-term headwind of higher interest rates.  

Appealing valuation

Both of these ASX 300 shares are trading at a large discount to their underlying value – the net tangible assets (NTA) per unit includes the loans, the property values, cash in the bank and so on.

At 31 December 2025, Dexus Industria REIT reported NTA per security of $3.39 – it’s trading at a 28% discount to this. The Centuria Industrial REIT is trading at a 22% discount to its December 2025 NTA of $3.95.

I don’t know when the next interest rate cut will be, but when we enter that period, it could be a strong tailwind for property valuations and the unit prices of the ASX 300 shares. Of course, there are more ASX shares that could also be compelling buys today for passive income.

The post Forget term deposits! I’d buy these two ASX 300 shares instead appeared first on The Motley Fool Australia.

More reading

• 7 ASX 200 shares going ex-dividend today
• 5 things to watch on the ASX 200 on Monday
• Where should I invest inside SMSFs instead of property?
• Get paid huge amounts of cash to own these ASX dividend shares
• How much is needed in superannuation to target an $11,000 monthly passive income?

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.